Rounds Report: Aimmune Is Gaining Momentum While Editas Experiences Significant Insider Purchases – Seeking Alpha
|
Rounds Report: Aimmune Is Gaining Momentum While Editas Experiences Significant Insider Purchases
Seeking Alpha Interestingly, the company employs the gene-editing system coined CRISPR, which is highly prudent. It's a protein-RNA complex composed of either the protein Cas9 – the case for Crispr Therapeutics (NASDAQ:CRSP) – or Cpf1, each of which binds to a … |
